A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost.

MLA

Thongcharoen, Prasert, et al. “A Phase 1/2 Comparative Vaccine Trial of the Safety and Immunogenicity of a CRF01_AE (Subtype E) Candidate Vaccine: ALVAC-HIV (VCP1521) Prime with Oligomeric Gp160 (92TH023/LAI-DID) or Bivalent Gp120 (CM235/SF2) Boost.” Journal of Acquired Immune Deficiency Syndromes (1999), vol. 46, no. 1, Sept. 2007, pp. 48–55. EBSCOhost, https://doi.org/10.1097/QAI.0b013e3181354bd7.

APA

Thongcharoen, P., Suriyanon, V., Paris, R. M., Khamboonruang, C., de Souza, M. S., Ratto-Kim, S., Karnasuta, C., Polonis, V. R., Baglyos, L., Habib, R. E., Gurunathan, S., Barnett, S., Brown, A. E., Birx, D. L., McNeil, J. G., & Kim, J. H. (2007). A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. Journal of Acquired Immune Deficiency Syndromes (1999), 46(1), 48–55. https://doi.org/10.1097/QAI.0b013e3181354bd7

Chicago

Thongcharoen, Prasert, Vinai Suriyanon, Robert M Paris, Chirasak Khamboonruang, Mark S de Souza, Silvia Ratto-Kim, Chitraporn Karnasuta, et al. 2007. “A Phase 1/2 Comparative Vaccine Trial of the Safety and Immunogenicity of a CRF01_AE (Subtype E) Candidate Vaccine: ALVAC-HIV (VCP1521) Prime with Oligomeric Gp160 (92TH023/LAI-DID) or Bivalent Gp120 (CM235/SF2) Boost.” Journal of Acquired Immune Deficiency Syndromes (1999) 46 (1): 48–55. doi:10.1097/QAI.0b013e3181354bd7.